PD-L1 is associated with a wide range of cancers, including non-small cell lung cancer (NSCLC), melanoma, bladder cancer, renal cell carcinoma, and head and neck squamous cell carcinoma. The expression of PD-L1 in these cancers often correlates with poor prognosis and advanced stage disease.
